Literature DB >> 2421173

Mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine and its effects in L1210 mouse leukemia cells.

J Veselý, A Pískala.   

Abstract

Ara-5AC depresses the growth of L1210 cells in vivo in a manner that is schedule-independent and at the dose levels which are similar to those of ara-C. The 50% inhibitory concentration for ara-5AC in L1210 system is about 0.75 microM. In distinction to ara-C the drug does not elicit the proliferation of proerythroblasts in the mouse bone marrow. It is phosphorylated by dCyd kinase, and the respective Km value is 70 microM. Ara-5AC is incorporated into DNA and almost completely blocks the incorporation of thymidine at a concentration of 10 microM.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421173

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  5 in total

1.  Phase II study of fazarabine in advanced head and neck cancer. A Southwest Oncology Group study.

Authors:  J P Kuebler; B Metch; D E Schuller; M Keppen; H E Hynes
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

Review 2.  Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials.

Authors:  J L Grem; D D Shoemaker; D F Hoth; S A King; J Plowman; D Zaharko; C K Grieshaber; S D Harrison; J C Cradock; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

3.  Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma.

Authors:  E S Casper; G K Schwartz; D P Kelsen
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

4.  Phase I trial of a 72-h continuous-infusion schedule of fazarabine.

Authors:  R Amato; D Ho; S Schmidt; I H Krakoff; M Raber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: a Southwest Oncology Group study.

Authors:  S K Williamson; J J Crowley; R B Livingston; T J Panella; J W Goodwin
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.